[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100436131":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":17,"locations":7,"responsibleParty":26,"collaborators":7,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":7,"acronym":7,"eligibilityCriteria":33,"healthyVolunteers":30,"sex":7,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":34,"phases":7,"briefSummary":35,"conditions":36,"keywords":7,"overallStatus":38,"whyStopped":7,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":43,"locationsCount":7},{"fullName":5,"class":6},"Chiesi Farmaceutici S.p.A.","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":12},"DRUG","Velmanase Alfa",[13,14,15,16],"Lamzede","Lamazym","rhLAMAN","recombinant human alpha-mannosidase",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Expanded Access","CONTACT","(888) 661-9260","GRD.EAP@chiesi.com",{"name":24,"role":20,"phone":7,"phoneExt":7,"email":25},"Clinical Trials","clinicaltrials_info@chiesi.com",{"type":27,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100436131","expanded-access-to-velmanase-alfa-100436131",false,"NCT04959240","Expanded Access to Velmanase Alfa","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","Individual patient expanded access requests may be considered for patients who have no other treatment options.",[37],"Alpha-Mannosidosis","AVAILABLE","2023-09-22",{"date":41,"type":42},"2023-09-25","ACTUAL",{"name":5,"class":6}]